초록접수 현황
| 20F-137 | 구연 발표 |
Effect of Adjuvant chemotherapy for pathologic T2bN0M0 non-small cell lung cancer without invasion of adjacent structure
Wan Jin Hwang, Beatrice Chia-Hui Shih, Soyoung Lee, Woohyun Jung, Yoohwa Hwang, Jae Hyun Jeon, Kwhanmien Kim, Sanghoon Jheon, Sukki Cho
Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Seoul University College of Medicine, Seoul, Republic of Korea
Purpose : Adjuvant chemotherapy (ACT) improves survival in patients with complete resected non-small cell lung cancer (NSCLC) with nodal metastasis. In tumors of 4 cm or larger and node-negative NSCLC, survival benefit can be obtained by ACT. However, there was little data whether ACT might be effective in T2bN0M0 only based on tumor size without adjacent structure invasion such as visceral pleural invasion or trans-fissural invasion. Therefore, this study was analyzed the outcome of ACT in pathologic T2bN0M0 without invasion of adjacent structure.
Methods : Patients with pathologic T2bN0M0 NSCLC who underwent lobectomy and mediastinal LN dissection from 2003 to 2018 were evaluated. Presence of adjacent structure invasion (ASI) was defined visceral invasion or trans-fissural invasion. The Kaplan-Meier analysis was applied for the overall survival (OS) and recurrence-free survival (RFS) and compared by log-rank test.
Results : Among 79 patients with T2bN0M0, there were 32 patients (41%) who received ACT. The ACT was associated with improved 5-year RFS [79% of ACT (-), 85% of ACT (+)], statistically insignificant (p=0.464) (Fig. A). After stratification by ASI, there were 45 patients without ASI and 34 patients with ASI. In patients without ASI, 5-year RFS was not significantly different between ACT (-) and ACT (+) groups (86% vs 83%, p=927) (Fig. B). In contrast, although there was no statistical significance, 5-year RFS was higher in patients with ASI than without ASI (Fig. C).
Conclusion : For patients with pathologic T2bN0M0 without adjacent structure invasion, adjuvant chemotherapy might be avoided if lobar resection and complete mediastinal LN dissection is guaranteed.
Methods : Patients with pathologic T2bN0M0 NSCLC who underwent lobectomy and mediastinal LN dissection from 2003 to 2018 were evaluated. Presence of adjacent structure invasion (ASI) was defined visceral invasion or trans-fissural invasion. The Kaplan-Meier analysis was applied for the overall survival (OS) and recurrence-free survival (RFS) and compared by log-rank test.
Results : Among 79 patients with T2bN0M0, there were 32 patients (41%) who received ACT. The ACT was associated with improved 5-year RFS [79% of ACT (-), 85% of ACT (+)], statistically insignificant (p=0.464) (Fig. A). After stratification by ASI, there were 45 patients without ASI and 34 patients with ASI. In patients without ASI, 5-year RFS was not significantly different between ACT (-) and ACT (+) groups (86% vs 83%, p=927) (Fig. B). In contrast, although there was no statistical significance, 5-year RFS was higher in patients with ASI than without ASI (Fig. C).
Conclusion : For patients with pathologic T2bN0M0 without adjacent structure invasion, adjuvant chemotherapy might be avoided if lobar resection and complete mediastinal LN dissection is guaranteed.
첨부파일 : Figure.pptx
책임저자: Sukki Cho
Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Seoul University College of Medicine, Seoul, Republic of Korea
발표자: Wan Jin Hwang, E-mail : 82375@snubh.org